Loading market dashboard
Avis Budget Group, Inc.
CARIndustrialsNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion Company reported strong positive preclinical results demonstrating significantly enhanced anti-tumor activity of anti-CD-19 CAR T cells when combined with DNase I in multiple preclinical models of hematologic cancers Investigator initiated study to be conducted at Tel-Aviv Sourasky Medical Center ("Sourasky Center") FRAMINGHAM, MA / ACCESS Newswire / June 4, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. (PeriNess), has informed the Company that it received formal approval from the Israeli Ministry of Health and the respective Institutional Review Board to conduct an exploratory clinical study of a combination systemic DNase I with anti-CD19 CAR T Cells in large B cell lymphoma (LBCL) patients.
BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising preliminary clinical data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), will be presented during a late-breaking session at the European Hematology Association (EHA) 2026 Congress, taking place June 11-14, 2026, in Stockholm, Sweden.
New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies Data highlight potential of DNase I to improve CAR-T cell expansion, reduce exhaustion and enhance tumor control across hematologic cancer models Findings support continued clinical development of DNase I as a combinatorial strategy to augment CAR-T cell therapies in difficult-to-treat cancers Data to be presented today as a poster presentation at the ASCO 2026 annual meeting FRAMINGHAM, MA / ACCESS Newswire / June 1, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced positive preclinical data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating that DNase I significantly enhances CAR-T cell expansion, persistence, and antitumor efficacy in aggressive hematologic cancer models. Presentation Details: Session Title: Hematologic Malignancies - Plasma Cell Dyscrasia (Poster Session) Abstract Title: Targeting cfDNA and NETs with DNase I to augment CAR-T cell function and antitumor efficacy Poster Board: 410 Presentation Date & Time: June 1, 2026, 9:00 AM - 12:00 PM CDT Presenter: Alexey V.
Optimization of chelator-to-antibody ratio (CAR) is a key design parameter for next-generation radioconjugates, presenting tunable levers Actinium is utilizing to engineer more effective drug candidates Optimized CAR improved tumor targeting, internalization, and pharmacokinetics of 225Ac-labeled antibodies Lower-CAR conjugates preserved tumor targeting while reducing off-target liver and spleen uptake, supporting a wider therapeutic window that may enable higher, safer dosing Findings reinforce Actinium's proprietary radiochemistry expertise and directly support the Company's broader radioconjugate pipeline a capability that applies to every program from the platform NEW YORK, June 1, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, on May 31, 2026 presented new radiochemistry data at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting taking place in Los Angeles, California. The poster presented a systematic evaluation of chelator-to-antibody ratio (CAR) optimization for Actinium-225 (225Ac)-labeled antibody radioconjugates, a critical but often underappreciated design parameter that directly influences radiolabeling efficiency, antigen binding, internalization, and biodistribution.
Avis Budget (CAR) reported earnings 30 days ago. What's next for the stock?
On May 28, 2026, Avis Budget Group Inc (CAR) shares rose by 5.9%, bringing the current price to $174.88. This latest movement comes amid a 52-week range that ha
Avis Budget is expanding mobility partnerships and premium services as it positions itself beyond traditional car rentals.
PARSIPPANY, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis Budget Finance, Inc. (together, the “Issuers”), priced a private offering of $300 million aggregate principal amount of additional 8.000% Senior Notes due 2031 (the “Notes”) in a private offering. The Notes will be issued as additional notes under the Indenture, dated as of November 22, 2023, pursuant to which the Issuers previously issued $500 million aggregate principal amount of 8.000% Senior Notes due 2031. The Notes will have a maturity date of February 15, 2031. The closing of the offering of the Notes is expected to occur on May 29, 2026, subject to customary closing conditions. The Notes were priced at 100.500% of its face value and will be guaranteed on a senior unsecured basis by the Company and certain of its U.S. subsidiaries.
TTEC's AI-driven turnaround, improving free cash flow and a stronger liquidity position it ahead of CAR's volatile recovery efforts.
Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, with the potential to support curative outcomes Company plans to commercialize the reagents through corporate partners focused on CAR-T and NK-cell therapies, including developers and manufacturers MIRAMAR, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing first-in-class fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia, today announced that it has exercised its option to regain full ex vivo rights to HCW9206 and HCW9201, two commercial-ready compounds as reagents, from its licensee, Wugen Inc. Wugen held exclusive worldwide rights to these two compounds for ex vivo, cell-based therapy applications.
PARSIPPANY, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis Budget Finance, Inc. (together, the “Issuers”), intend, subject to market and other customary conditions, to offer $300 million aggregate principal amount of additional 8.000% Senior Notes due 2031 (the “Notes”) in a private offering.
Lyell Immunopharma NASDAQ: LYEL President and CEO Lynn Seely outlined the company's clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session moderated by Stephen Willey, senior biotech analyst at Stifel.
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs will be featured at the American Society of Cancer Oncology Annual Meeting to be held in Chicago, IL, May 29 – June 2, 2026 and at the European Congress of Rheumatology being held in London, UK, June 3-6, 2026.
HANGZHOU, China--(BUSINESS WIRE)--Qihan Biotech, a biotechnology company dedicated to applying high-throughput, multiplexed gene editing technologies to cell therapy and organ transplantation, announced today that QT-019C has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). QT-019C is a universal allogeneic CAR-T cell therapy independently developed by Qihan Biotech using the company's proprietary intellectual property. A distinguishing innovat.
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced upcoming data presentations at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress from June 3 – 6, 2026 in London. The five accepted abstracts will be delivered as one late-breaking oral presentation, one oral presentation, one poster view, one poster tour and one publication only.
CAR's pricing rebound and tighter fleet management are boosting utilization and improving depreciation trends.
CAR's pricing recovery and Waymo partnership offer long-term potential, but April's 70% stock collapse exposed major volatility risks.
Cabaletta Bio, Inc. is reaffirmed as a Buy despite recent share price volatility, driven by tangible clinical and manufacturing progress. Key catalysts include registrational trials for rese-cel in myositis, promising early data in myasthenia gravis and pemphigus vulgaris, and upcoming SLE and SSc readouts. Rese-cel's outpatient-friendly safety profile, removal of preconditioning, and scalable manufacturing platform position CABA for significant autoimmune market opportunities.
SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of preclinical data demonstrating that a surrogate SG293, an in vivo CAR T cell therapy, achieved cell-specific delivery, robust and dose-dependent CAR T cell generation, and deep B cell depletion in non-human primates (NHPs) without the use of lymphodepleting chemotherapy. SG293 is a CD8-targeted fusosome that delivers the genetic material to make CD19-directed CAR T cells.
Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting WESTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), will announce preclinical data demonstrating the in vivo generation of CAR-T cells and deep systemic B-cell depletion achieved with its MDX3001 candidate in animal models.
Multiple patients have survived substantially beyond expected median survival, including onepatient who survived 28 months and several patients who remain alive with continued follow-up Lira-cel clinical trial featured in presentation at the International Society for Cell & Gene Therapy2026 Annual Meeting SAN JOSE, Calif., May 11, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, the Company's follicle-stimulating hormone receptor ("FSHR")-targeted CAR-T therapy being developed for the treatment of recurrent ovarian cancer.
Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Canadian Apartment Properties Real Estate Investment Trust ("CAPREIT") (TSX: CAR.UN) announced today its operating and financial results for the three months ended March 31, 2026.
Avis Budget's Q1 loss misses estimates as fleet charges stay high, but revenues beat and utilization hit a first-quarter record in more than 15 years.
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs FT819, FT839, and FT836, will be featured at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting to be held in Boston, MA, May 11–15, 2026. Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus (SLE) arm of its ongoing Phase 1 trial evaluating FT819 in Regimen B, where FT819 is added to background maintenance therapy without the use of conditioning chemotherapy to drive B cell depletion and improve patient outcome.
Bristol Myers Squibb faces a major patent cliff but is well-equipped with a robust pipeline and significant CAR-T optionality. BMY trades at a discounted 9.4x forward P/E, reflecting patent cliff fears, yet offers 15-20% base case upside plus a 4.3% dividend yield. The 2026 catalyst stack includes Milvexian, Iberdomide, Cobenfy, and Sotyktu, any of which could drive a rerating to 10x-11x forward P/E.
Pre-Market Stock Futures: Futures are trading mixed as we get ready to finish off another wild week. What a difference a day makes: after a flat-to-down Wednesday, all the major indices exploded higher on Thursday and closed solidly in the green. Big earnings for members of the Magnificent 7, oil prices falling somewhat, and while... Here Are Friday's Top Wall Street Analyst Research Calls: Avis Budget, Caterpillar, Celestica, Commvault Systems, Ciena, Dutch Bros. e.l.f. Beauty, Hershey, Roblox, and More
Shares of Hertz (NASDAQ:HTZ) are up 13% on Thursday at roughly $6.35, while Avis Budget Group (NASDAQ:CAR | CAR Price Prediction) stock is only up 2% to around $184.50.
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that clinical data from the Company's off-the-shelf CAR T-cell product candidate, FT819, will be featured at the Congress of Clinical Rheumatology – East meeting, being held in Destin, FL on April 30 - May 3, 2026. The Company is participating in a Poster Rounding Session and will present an encore of its clinical data from the systemic lupus erythematosus (SLE) study arm of its ongoing Phase 1 trial evaluating FT819 in various autoimmune diseases.
The rental car company says a hedge-fund firm behind the big swings owes it money because of a niche trading rule.
Avis Budget Group, Inc. (CAR) Q1 2026 Earnings Call Transcript
Although the revenue and EPS for Avis Budget (CAR) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Avis Budget Group, Inc. (NASDAQ:CAR) shares are trading lower Wednesday after the company reported mixed first-quarter results.
Shares of Avis Budget Group (NASDAQ:CAR | CAR Price Prediction) are down roughly 12% in early Wednesday trading after the company released a disappointing Q1 2026 earnings report before market open (BMO).
Avis Budget Group (CAR) came out with a quarterly loss of $8.01 per share versus the Zacks Consensus Estimate of a loss of $6.83. This compares to a loss of $14.35 per share a year ago.
Avis Budget Group (NASDAQ: CAR | CAR Price Prediction) stock surged from roughly $148 a share on March 27, 2026, to a 52-week high of $847.70 in a matter of weeks, then crumpled back to $182.01 by April 28.
BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) will present its most recent clinical data from its lead dual-targeting chimeric antigen receptor T-cell (“CAR-T”) therapy product candidate, TPST-2003, at the International Society for Cell & Gene Therapy (“ISCT”) Scientific Annual Meeting in Dublin, May 6-9, 2026. Updates will include the latest data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, as well as progress in Tempest's other dual-targeting CAR-T pipeline programs.
TFI International Inc. (TFII) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.76 per share a year ago.
SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting preclinical data from SG293, its CD19-directed in vivo CAR T product candidate, has been accepted for oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting taking place May 11-15, 2026 in Boston, MA.
No announcement or breakthrough caused the surge; just a classic short squeeze story involving an artificially-limited float and unbridled risk-seeking behavior.
The stock had turned into a meme before falling back to earth in recent days.
In my opinion, Legend Biotech Corporation is an attractive acquisition target for Johnson & Johnson. Carvykti, which they are jointly developing, is quickly catching up in sales with Darzalex, J&J's blockbuster for the treatment of multiple myeloma. So, sales of Carvykti reached $597 million in Q1, up 61.8% year-on-year, beating my 'best case' scenario by $15 million.
Avis Budget Group Inc (NASDAQ:CAR) shares are trading marginally higher Friday morning as traders reassess a short-seller's claims that the stock's earlier spike was driven by a manufactured short squeeze rather than fundamentals.
Despite the stock falling 48% today, Avis Budget is still up 129% over the last month.
Tim Biggam turns to three stocks he believes have overextended moves in recent trading session. To the upside: Micron (MU), which has rallied over 40% in the last month.
Avis Budget Group (CAR) is now seeing a sharp reversal after an extraordinary run, with shares falling more than 57% over the past two sessions, a move that com
After an incredible triple-digit runup in just three weeks' time, the rug's suddenly being pulled out from underneath the rally. The sudden and sharp reversal, however, isn't exactly surprising.
Avis Budget Group shares are tumbling as investors worry a potential equity offering could ease the recent short squeeze and pressure the stock.
Shares of Avis Budget Group (NASDAQ:CAR | CAR Price Prediction) are cratering in Thursday trading, with the stock last changing hands near $290 after closing Wednesday at $443.94.
Shares of Avis Budget Group Inc (NASDAQ:CAR) are trading sharply lower Thursday morning after a scathing report by Fugazi Research alleged the stock's massive valuation was artificially inflated by a “prisoners' dilemma” between two major hedge funds. Benzinga has reached out to Avis Budget Group for comment regarding the allegations.
The Center for Cancer &Blood Disorders receives authorization to administer FDA-approved CAR T-cell therapy; begins treating 1st community oncology patient
Cartesian Therapeutics receives a buy rating, driven by a differentiated mRNA CAR-T approach for autoimmune diseases and strong insider/institutional support. RNAC's lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b, surpassing current biologics in durability and efficacy. The ongoing Phase 3 AURORA trial, with FDA SPA agreement and 100 patients, is a pivotal binary catalyst; $126.9M cash runway extends into mid-2027.
Avis Budget's stock chart just sent some bearish signals to suggest a hard landing is in the works.
PARSIPPANY, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its first quarter 2026 financial results at 7:00 a.m.
Avis stock is off $168 per share, or 23.5%, to $547 in a wild session that saw it trade at $848 shortly after the opening.
Avis Budget Group (NASDAQ:CAR | CAR Price Prediction) shares are up 13% in early trading Wednesday, continuing a rally that has now become one of the more extraordinary moves in recent market memory.
Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trial SAN JOSE, Calif., April 22, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Cheryl Cox, MHA, Operations Director of the Cell Therapies and Gene Expression Engineering Facility at Moffitt Cancer Center, will be presenting at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, being held May 6 – 9, 2026, in Dublin, Ireland.
On April 21, 2026, Avis Budget Group Inc (CAR) shares rose 17.3% today, trading at $713.97. This surge comes after a remarkable performance over the past year,
Eli Lilly and Co (NYSE:LLY)'s acquisition of Kelonia Therapeutics is being seen as a positive step for long-term pipeline building, even as the target's lead assets remain in early clinical development, according to UBS analysts. The $3.25 billion deal, announced on Monday, is among the largest to date in the in vivo CAR-T space.
Navitas has become a meme stock as it attempts a transformation into an AI power chip company.
The “meme stock” spirits of years past have been reawakened on Wall Street this Tuesday, as Avis Budget (NASDAQ: CAR) and Beyond Meat (NASDAQ: BYND) – both opened about 20% higher. The catalyst?
